In Mice With Type 2 Diabetes, a Vascular Endothelial Growth Factor (VEGF)-Activating Transcription Factor Modulates VEGF Signaling and Induces Therapeutic Angiogenesis After Hindlimb Ischemia

• DOI: 10.2337/db06-0999
• Publication Date: 2007-02-27T18:14:43Z
• Authors: Yongjun Li; Surovi Hazarika; Donghua Xie; Anne M. Pippen; Christopher D. Ko...; Brian H. Annex
• Keywords: Therapeutic angiogenesis; Arteriogenesis

Peripheral arterial disease is a major complication of diabetes. The ability to promote therapeutic angiogenesis may be limited in Type 2 diabetes was induced by high-fat feeding C57BL/6 mice (n = 60). Normal chow-fed 20) had no Mice underwent unilateral femoral artery ligation and excision. A plasmid DNA encoded an engineered transcription factor designed increase vascular endothelial growth expression (ZFP-VEGF). On day 10 after the operation, ischemic limbs received 125 microg ZFP-VEGF or control. were killed 3, 10, 20 days injection 10/group, at each time point). Limb blood flow measured laser Doppler perfusion imaging. VEGF mRNA examined real-time PCR. VEGF, Akt, phospho-Akt protein enzyme-linked immunosorbent assay. Capillary density, proliferation, apoptosis assessed histologically. Compared with normal mice, greater protein, reduced phospho-Akt-to-Akt ratio before ligation, impaired recovery ligation. At 3 injection, diabetes, gene transfer increased signaling. later points, resulted better recovery. Gene able type